Why the study?
Does cardiac resynchronization therapy benefit patients with end-stage congestive heart failure and coexisting atrial fibrillation?
Does cardiac resynchronization therapy benefit patients with end-stage congestive heart failure and coexisting atrial fibrillation?
Answers are grounded in this paper and cite their sources.
This review examines the available evidence on the benefits and limitations of cardiac resynchronization therapy in patients with congestive heart failure and atrial fibrillation, a population often excluded from major trials.
Congestive heart failure (CHF) and atrial fibrillation (AF) are two increasingly common conditions that predispose to each other and frequently coexist. Cardiac resynchronization therapy(CRT) has emerged as an important therapeutic modality for selected patients with end-stage CHF. However, despite the high prevalence of AF in patients eligible for CRT, almost all the randomized clinical trials that validated the benefit of resynchronization therapy excluded patients with preexisting AF. In this review, we examine the available evidence on the benefits and limitations of CRT in patients with AF and discuss recent data that narrowed the knowledge gap on this topic.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2012) conducted a review in Congestive heart failure and atrial fibrillation. Cardiac resynchronization therapy was evaluated.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: